Home Cart Sign in  
Chemical Structure| 361154-30-5 Chemical Structure| 361154-30-5

Structure of Ac4ManNAz
CAS No.: 361154-30-5

Chemical Structure| 361154-30-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Synonyms: N-Azidoacetylmannosamine-tetraacylated; N-Azidoacetyl-D-mannosamine

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ac4ManNAz

CAS No. :361154-30-5
Formula : C16H22N4O10
M.W : 430.37
SMILES Code : O=C(N[C@@H]1C(OC(C)=O)O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O)CN=[N+]=[N-]
Synonyms :
N-Azidoacetylmannosamine-tetraacylated; N-Azidoacetyl-D-mannosamine
MDL No. :MFCD26961126
InChI Key :HGMISDAXLUIXKM-LIADDWGISA-N
Pubchem ID :71311757

Safety of Ac4ManNAz

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
pcMSCs 20 µM 4 days Optimize the expression of azido groups on the surface of pcMSCs J Extracell Vesicles. 2025 Feb;14(2):e70044
4T1 cells 2.4 mg/mL 48 h To verify the labeling efficiency of IP10-Az@MNs on tumor cells, results showed successful incorporation of N3 groups into cell surface glycans. Adv Sci (Weinh). 2025 Apr;12(13):e2416841
Human lung adenocarcinoma cells (A549) 10 μM and 50 μM 3 days Analyze the effects of Ac4ManNAz on gene expression, physiological and biochemical properties of cells. Results showed that 50 μM Ac4ManNAz significantly reduced major cellular functions, including energy generation capacity, cellular infiltration ability and channel activity; while 10 μM Ac4ManNAz had minimal effects on cellular systems and provided sufficient labeling efficiency. Theranostics. 2017 Mar 1;7(5):1164-1176
MCF-7 breast cancer cells 50 μM 3 days Successfully engineered high-density azide groups (3.23×107/cell) on tumor cell surfaces via metabolic glycoengineering for subsequent bio-orthogonal click chemistry to enhance cellular uptake of nanocomposites. Theranostics. 2020 Apr 6;10(12):5305-5321
Jurkat T cells 25 μM 3 days Metabolically label cell-surface sialoglycoconjugates, followed by detection of FLAG-labeled glycoconjugates via flow cytometry. Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):1821-6
PC3-ML2 cells 20 μM 24 h To confirm the metabolic labeling efficiency of Ac4ManNAz on the cell surface and validate the cell surface sialylation labeling by flow cytometry and confocal microscopy. Results showed that Ac4ManNAz-treated cells exhibited a significant increase in FITC-specific fluorescence intensity. Mol Cell Proteomics. 2011 Jun;10(6):M110
MDA-MB-231 breast cancer cells 50 μM 24 h Monitoring glycosylation processes in live cells using FTIR spectroscopy, showing successful incorporation of Ac4ManNAz into cell membrane glycoproteins with a distinct azide peak detected at 2122 cm−1. Talanta. 2020 May 1;211:120737

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice MCF-7 breast tumor model Intratumoral injection 40 mg/kg Once daily for 3 days Generated azide groups on tumor cell surfaces via metabolic glycoengineering, enabling DBCO-modified nanocomposites to achieve tumor-specific targeting, significantly enhancing tumor enrichment (4.6x) and chemo-photothermal synergistic therapy efficacy (96.1% inhibition rate). Theranostics. 2020 Apr 6;10(12):5305-5321

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.32mL

0.46mL

0.23mL

11.62mL

2.32mL

1.16mL

23.24mL

4.65mL

2.32mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records